Postoperative Expressions of TRACP5b and CA125 in Patients With Breast Cancer and Their Values for Monitoring Bone Metastasis

J BUON. Mar-Apr 2020;25(2):688-695.

Abstract

Purpose: To explore the diagnostic values of serum tartrate-resistant acid phosphatase 5b (TRACP5b) and serum carbohydrate antigen 125 (CA125) for bone metastasis of breast cancer.

Methods: 118 patients pathologically diagnosed with breast cancer in the second People's Hospital of Lianyungang from September 2014 to June 2017 were selected. Among them, 60 patients who were confirmed with bone metastasis by whole-body bone imaging combined with clinical manifestations and other imaging methods were included in a bone metastasis group, and 58 patients who were confirmed without bone metastasis were included in a non-bone metastasis group. Another 61 patients who were pathologically confirmed with benign breast lesion formed a benign lesion group. Enzyme-linked immunosorbent assay (ELISA) was used to detect TRACP5b level and electrochemiluminescence (ECL) was used to detect CA125 level.

Results: The expression levels of TRACP5b and CA125 in the bone metastasis group were significantly higher than those in the non-bone metastasis and benign lesion groups (p<0.05), and the expression levels in the non-bone metastasis group were higher than those in the benign lesion group (p<0.05). In bone metastasis of breast cancer, the expression level of TRACP5b was correlated with the number of tumor nodules, lymph node metastasis, tumor local infiltration and TNM staging (p<0.05), while the expression level of CA125 was correlated with the number of tumor nodules, lymph node metastasis and TNM staging (p<0.05). Logistic regression analysis showed that TNM staging, estrogen receptor (ER), TRACP5b, and CA125 were risk factors for bone metastasis of breast cancer patients.

Conclusion: In conclusion, TRACP5b and CA125 may be involved in the occurrence and progression of bone metastasis of breast cancer. Detection of TRACP5b and CA125 has good sensitivity and specificity in diagnosing bone metastasis of breast cancer, so TRACP5b and CA125 may become new biomarkers for diagnosing the disease.